PT  - JOURNAL ARTICLE
AU  - Elf, Anna-Karin
AU  - Bernhardt, Peter
AU  - Hofving, Tobias
AU  - Arvidsson, Yvonne
AU  - Forssell-Aronsson, Eva
AU  - Wängberg, Bo
AU  - Nilsson, Ola
AU  - Johanson, Viktor
TI  - NAMPT Inhibitor GMX1778 Enhances the Efficacy of <sup>177</sup>Lu-DOTATATE Treatment of Neuroendocrine Tumors
AID  - 10.2967/jnumed.116.177584
DP  - 2017 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 288--292
VI  - 58
IP  - 2
4099  - http://jnm.snmjournals.org/content/58/2/288.short
4100  - http://jnm.snmjournals.org/content/58/2/288.full
SO  - J Nucl Med2017 Feb 01; 58
AB  - Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. Our study evaluated the potential radiosensitizing effects of inhibition of nicotineamide phosphoribosyltransferase on 177Lu-DOTATATE treatment in a NET model. Methods: Nude mice xenografted with the human NET cell line GOT1 were treated with semiefficient doses of 177Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide phosphoribosyltransferase inhibitor GMX1778 (100 mg/kg/wk, orally). Results: Median time to tumor progression (tumor volume larger than at day 0) was 3 d for controls, 7 d for single-dose GMX1778, 28 d for single-dose 177Lu-DOTATATE, 35 d for 3 weekly doses of GMX1778, and 98 d for combined treatment with 177Lu-DOTATATE and GMX1778 × 1. After 177Lu-DOTATATE and 3 weekly doses of GMX1778, none of the tumors progressed within 120 d. Conclusion: GMX1778 enhances the efficacy of 177Lu-DOTATATE treatment and induces a prolonged antitumor response.